Research ExplorerPublicationsGraft-versus-host disease and impact on relapse in myelofibr...

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

Standard

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. / Oechsler, Sofia; Gagelmann, Nico; Wolschke, Christine; Janson, Dietlinde; Badbaran, Anita; Klyuchnikov, Evgeny; Massoud, Radwan; Rathje, Kristin; Richter, Johanna; Schäfersküpper, Mathias; Niederwieser, Christian; Kunte, Ameya; Heidenreich, Silke; Ayuk, Francis; Kröger, Nicolaus.

In: BONE MARROW TRANSPL, Vol. 59, No. 4, 04.2024, p. 550-557.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Oechsler, S, Gagelmann, N, Wolschke, C, Janson, D, Badbaran, A, Klyuchnikov, E, Massoud, R, Rathje, K, Richter, J, Schäfersküpper, M, Niederwieser, C, Kunte, A, Heidenreich, S, Ayuk, F & Kröger, N 2024, 'Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation', BONE MARROW TRANSPL, vol. 59, no. 4, pp. 550-557. https://doi.org/10.1038/s41409-024-02220-7

APA

Oechsler, S., Gagelmann, N., Wolschke, C., Janson, D., Badbaran, A., Klyuchnikov, E., Massoud, R., Rathje, K., Richter, J., Schäfersküpper, M., Niederwieser, C., Kunte, A., Heidenreich, S., Ayuk, F., & Kröger, N. (2024). Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. BONE MARROW TRANSPL, 59(4), 550-557. https://doi.org/10.1038/s41409-024-02220-7

Vancouver

Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. BONE MARROW TRANSPL. 2024 Apr;59(4):550-557. https://doi.org/10.1038/s41409-024-02220-7

Bibtex

@article{6208e7fe99e54765a1dcdeb8e0d58fe6,
title = "Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment for myelofibrosis (MF). Relapse occurs in 10-30% and remains a major factor for dismal outcomes. Previous work suggested that graft-versus-host disease (GVHD) might be associated with risk of relapse. This study included 341 patients undergoing their first (n = 308) or second (n = 33) alloHSCT. Anti-T-lymphocyte or antithymocyte globulin was used for GVHD prophylaxis in almost all patients. Median time to neutrophile and platelet engraftment was 13 days and 19 days, respectively. The cumulative incidence of acute GVHD grade II-IV was 41% (median, 31 days; range, 7-112). Grade III-IV acute GVHD was observed in 22%. The cumulative incidence of chronic GVHD was 61%. Liver was affected in 23% of acute GVHD cases and 46% of chronic GVHD cases. Severe acute GVHD was associated with high non-relapse mortality. The development of acute GVHD grade II and moderate GVHD was an independent factor for reduced risk for relapse after transplantation without increased risk for non-relapse mortality, while especially acute GVHD grade IV was associated with high non-relapse mortality. Last, we identified that ongoing response to ruxolitinib, accelerated-phase MF at time of transplantation and splenectomy prior to transplantation were independent predictors for relapse.",
author = "Sofia Oechsler and Nico Gagelmann and Christine Wolschke and Dietlinde Janson and Anita Badbaran and Evgeny Klyuchnikov and Radwan Massoud and Kristin Rathje and Johanna Richter and Mathias Sch{\"a}fersk{\"u}pper and Christian Niederwieser and Ameya Kunte and Silke Heidenreich and Francis Ayuk and Nicolaus Kr{\"o}ger",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = apr,
doi = "10.1038/s41409-024-02220-7",
language = "English",
volume = "59",
pages = "550--557",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

AU - Oechsler, Sofia

AU - Gagelmann, Nico

AU - Wolschke, Christine

AU - Janson, Dietlinde

AU - Badbaran, Anita

AU - Klyuchnikov, Evgeny

AU - Massoud, Radwan

AU - Rathje, Kristin

AU - Richter, Johanna

AU - Schäfersküpper, Mathias

AU - Niederwieser, Christian

AU - Kunte, Ameya

AU - Heidenreich, Silke

AU - Ayuk, Francis

AU - Kröger, Nicolaus

N1 - © 2024. The Author(s).

PY - 2024/4

Y1 - 2024/4

N2 - Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment for myelofibrosis (MF). Relapse occurs in 10-30% and remains a major factor for dismal outcomes. Previous work suggested that graft-versus-host disease (GVHD) might be associated with risk of relapse. This study included 341 patients undergoing their first (n = 308) or second (n = 33) alloHSCT. Anti-T-lymphocyte or antithymocyte globulin was used for GVHD prophylaxis in almost all patients. Median time to neutrophile and platelet engraftment was 13 days and 19 days, respectively. The cumulative incidence of acute GVHD grade II-IV was 41% (median, 31 days; range, 7-112). Grade III-IV acute GVHD was observed in 22%. The cumulative incidence of chronic GVHD was 61%. Liver was affected in 23% of acute GVHD cases and 46% of chronic GVHD cases. Severe acute GVHD was associated with high non-relapse mortality. The development of acute GVHD grade II and moderate GVHD was an independent factor for reduced risk for relapse after transplantation without increased risk for non-relapse mortality, while especially acute GVHD grade IV was associated with high non-relapse mortality. Last, we identified that ongoing response to ruxolitinib, accelerated-phase MF at time of transplantation and splenectomy prior to transplantation were independent predictors for relapse.

AB - Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment for myelofibrosis (MF). Relapse occurs in 10-30% and remains a major factor for dismal outcomes. Previous work suggested that graft-versus-host disease (GVHD) might be associated with risk of relapse. This study included 341 patients undergoing their first (n = 308) or second (n = 33) alloHSCT. Anti-T-lymphocyte or antithymocyte globulin was used for GVHD prophylaxis in almost all patients. Median time to neutrophile and platelet engraftment was 13 days and 19 days, respectively. The cumulative incidence of acute GVHD grade II-IV was 41% (median, 31 days; range, 7-112). Grade III-IV acute GVHD was observed in 22%. The cumulative incidence of chronic GVHD was 61%. Liver was affected in 23% of acute GVHD cases and 46% of chronic GVHD cases. Severe acute GVHD was associated with high non-relapse mortality. The development of acute GVHD grade II and moderate GVHD was an independent factor for reduced risk for relapse after transplantation without increased risk for non-relapse mortality, while especially acute GVHD grade IV was associated with high non-relapse mortality. Last, we identified that ongoing response to ruxolitinib, accelerated-phase MF at time of transplantation and splenectomy prior to transplantation were independent predictors for relapse.

U2 - 10.1038/s41409-024-02220-7

DO - 10.1038/s41409-024-02220-7

M3 - SCORING: Journal article

C2 - 38321269

VL - 59

SP - 550

EP - 557

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 4

ER -